Adlyxin and Soliqua Join a Crowded Market of Injectable Diabetes Meds

Adlyxin (ad-LIKS-in) and Soliqua (soh-LEE-kwa) will be two new once-daily injectable meds for type 2 diabetes...and more are coming.

Adlyxin (lixisenatide) is the sixth GLP-1 agonist for diabetes. Think of it as similar to Byetta...but it's once-daily instead of BID.

Soliqua is the first insulin/GLP-1 agonist combo to hit the market. It contains Lantus (insulin glargine U-100) plus Adlyxin.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote